Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation
Authors
Keywords
Transverse myelitis, Infliximab, Immune-related adverse events, Checkpoint inhibitor, Radiation
Journal
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-12-22
DOI
10.1186/s40425-018-0471-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management
- (2018) Aarti Asnani Current Oncology Reports
- Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
- (2018) Christine A. Garcia et al. Journal for ImmunoTherapy of Cancer
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Severe cytokine release syndrome in a patient receiving PD-1-directed therapy
- (2017) Seth J. Rotz et al. PEDIATRIC BLOOD & CANCER
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Pathobiology of radiation myelopathy and strategies to mitigate injury
- (2015) C S Wong et al. SPINAL CORD
- CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
- (2015) Luis H. Camacho Cancer Medicine
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- Radiation Dose–Volume Effects in the Spinal Cord
- (2010) John P. Kirkpatrick et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Infliximab for the treatment of refractory scleritis
- (2009) P. Doctor et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
- (2009) David R. Minor et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
- (2008) R. L. Johnston et al. DIGESTIVE DISEASES AND SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started